Navidea biopharmaceuticals announces commencement of rights offering subscription period and updated terms of its previously announced rights offering

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the subscription period for the previously announced rights offering has commenced. if exercising subscription rights through a broker, dealer, bank or other nominee, rights holders should promptly contact their nominee and submit subscription documents and paymen
NAVB Ratings Summary
NAVB Quant Ranking